Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardio Diagnostics Holdings (CDIOW) Cost of Revenue (2022 - 2025)

Historic Cost of Revenue for Cardio Diagnostics Holdings (CDIOW) over the last 4 years, with Q1 2025 value amounting to $41820.0.

  • Cardio Diagnostics Holdings' Cost of Revenue rose 2156.27% to $41820.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $189864.0, marking a year-over-year increase of 3243.4%. This contributed to the annual value of $182446.0 for FY2024, which is 1509.77% up from last year.
  • Latest data reveals that Cardio Diagnostics Holdings reported Cost of Revenue of $41820.0 as of Q1 2025, which was up 2156.27% from $38206.0 recorded in Q4 2024.
  • In the past 5 years, Cardio Diagnostics Holdings' Cost of Revenue ranged from a high of $57779.0 in Q2 2024 and a low of $16369.0 during Q3 2022
  • For the 4-year period, Cardio Diagnostics Holdings' Cost of Revenue averaged around $36575.4, with its median value being $34402.0 (2024).
  • As far as peak fluctuations go, Cardio Diagnostics Holdings' Cost of Revenue surged by 12122.96% in 2023, and later tumbled by 3057.25% in 2024.
  • Cardio Diagnostics Holdings' Cost of Revenue (Quarter) stood at $27127.0 in 2022, then surged by 59.58% to $43288.0 in 2023, then dropped by 11.74% to $38206.0 in 2024, then rose by 9.46% to $41820.0 in 2025.
  • Its Cost of Revenue was $41820.0 in Q1 2025, compared to $38206.0 in Q4 2024 and $52059.0 in Q3 2024.